CTOs on the Move

Flagship Biosciences

www.flagshipbio.com

 
Flagship Biosciences, Inc. is a technology-driven tissue analysis services company delivering the most accurate and informative data for improved drug development and diagnostics. The company offers a full range of tissue analysis services using its award-winning technology to deliver breakthrough contextual data supported by a team of experienced pathology and scientific experts. It caters to pharmaceutical, biotechnology, and clinical diagnostic companies. Flagship Biosciences, Inc. was founded in 2009 and is headquartered in Westminster, Colorado.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details
Aymii Couzelis
Chief Information Officer Profile

Similar Companies

Armata Pharmaceuticals

Armata is a clinical-stage biotechnology company focused on the development of precisely targeted bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology.

Aptevo Therapeutics

Aptevo Therapeutics is a biotech company primarily focused on bringing novel oncology and hematology therapeutics to market. We leverage the innovative ADAPTIR™ platform technology, a unique approach to cancer immunotherapy, to improve outcomes for cancer patients.

Reprocell

Reprocell is a San Jose, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Vaxxas

Vaxxas is a privately held biotechnology company focused on enhancing the performance of existing and next-generation vaccines with its proprietary high-density microarray patch (HD-MAP). Vaxxas is targeting initial applications in infectious disease and oncology. In addition to HD-MAP HexaPro clinical studies of a COVID-19 vaccine patch, Vaxxas is performing demonstration work in preparation for clinical evaluation under contract with the United States Biomedical Advanced Research and Development Authority (BARDA) on pandemic vaccination solutions. Vaxxas core technology was initially developed at the University of Queensland. The company was founded with the completion of an initial equity financing led by OneVentures Innovation Fund I with co-investors Brandon Capital Partners, Brandon BioCatalyst, and US-based HealthCare Ventures, followed by a further financing led by OneVentures. OneVentures Innovation Fund I and Brandon BioCatalyst are supported by the Australian Government’s Innovation Investment Fund (IIF) program. The IIF is an Australian Government venture capital initiative that provides investment capital and managerial expertise through licensed venture capital fund managers to investee companies.

Gilva Biotechnology

Gilva Biotechnology is a Belmont, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.